A Phase 1b/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ripretinib in Combination with Binimetinib in Patients with Gastrointestinal Stromal Tumor (GIST) - MEKi Combo trial

Deciphera Pharmaceuticals, LLC0 个研究点目标入组 93 人开始时间: 2021年8月18日最近更新: 2023年9月26日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Deciphera Pharmaceuticals, LLC
入组人数: 93

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Escalation Phase:
•1. Participant must have at least progressed on imatinib or have documented intolerance to imatinib. There is no maximum number of prior treatments.
•2. ECOG PS of 0 or 1 at Screening.
•3. Adults =18 years of age with advanced GIST (unresectable or metastatic).
•4. Histologic diagnosis of GIST and must be able to provide an archival tumor tissue sample taken after the last anti-cancer treatment, otherwise, a fresh tumor biopsy is required.
•5. Must have at least 1 measurable target lesion according to mRECIST v1.1 (non-nodal lesions must be =1.0 cm in the long axis or = double the slice thickness in the long axis) within 21 days prior to the first dose of study drug.
•6. Female participants of childbearing potential must have a negative serum beta-human chorionic gonadotrophin (ß-hCG) pregnancy test at screening and negative pregnancy test at Cycle 1 Day 1 prior to the first dose of study drug.
•7. Participants of reproductive potential must agree to use two methods of contraception with one of those methods being highly effective (See Protocol Section 8.3).
•8. Adequate organ function and bone marrow reserve as indicated by the following laboratory assessments performed at screening:
•a. Absolute Neutrophil Count (ANC) =1000/µL
•b. Hemoglobin =8 g/dL
•c. Platelet count =75,000/µL
•d. Total bilirubin =1.5× the upper limit of normal (ULN)
•e. Aspartate transaminase (AST) and alanine transaminase (ALT) =3× ULN (or =5× ULN in the presence of hepatic metastases with approval of the medical monitor)
•f. Creatinine clearance =50 ml/min based on Cockcroft Gault estimation.
•g. Prothrombin time (PT), international normalized ratio (INR) and partial thromboplastin time (PTT) =1.5× ULN. Participants on a stable regimen of anticoagulant therapy for at least one month prior to the first dose of study drug may have PT/INR measurements >1.5× ULN if, in the opinion of the Investigator, the participant is suitable for the study after discussion with the medical monitor
•9. Resolution of all toxicities from prior therapy to = Grade 1 (or participant baseline) within 1 week prior to the first dose of study drug (excluding alopecia).
•10. Must be capable of understanding and complying with the protocol and the participant must have signed the informed consent form. A signed informed consent form (ICF) must be obtained before any study-specific procedures are performed.
•Expansion Phase:
•1. Participant must have progressed on imatinib or have a documented intolerance to imatinib. Participants must be naïve to all other systemic GIST therapy, including ripretinib or imatinib combinations.
•2. ECOG PS of 0 to 2 at Screening.
•3. Adults =18 years of age with advanced GIST (unresectable or metastatic).
•4. Histologic diagnosis of GIST and must be able to provide an archival tumor tissue sample taken after the last anti-cancer treatment, otherwise, a fresh tumor biopsy is required.
•5. Must have at least 1 measurable target lesion according to mRECIST v1.1 (non-nodal lesions must be =1.0 cm in the long axis or = double the slice thickness in the long axis) within 21 days prior to the first dose of study drug.
•6. Female participants of childbearing potential must have a negative serum beta-human chorionic gonadotrophin (ß-hCG) pregnancy test at screening and negative pregnancy test at Cycle 1 Day 1 prior to the first dose of study drug.
•7. Participants of reproductive potential must agree to use two methods of contraception with one of those methods being

排除标准

•Escalation Phase:
•1.Received anti-GIST therapy within 14days or 5×the half-life(whichever is shorter) of the first dose of study drug (investigational or approved therapy).
•2.Ongoing or prior participation in the DCC-2618-03-002 study
•3.Prior therapy with ripretinib
•4.Prior therapy with a MEK inhibitor
•5.Participants with a prior or concurrent malignancy whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of this clinical trial. For example, participants receiving adjuvant cancer treatment are not eligible if those medications are potentially active against the disease under study or excluded per protocol. NOTE: Participants with a history of breast cancer, requiring continued hormonal treatment (eg anti-estrogen or an aromatase inhibitor) may continue treatment. Participants with a history of prostate cancer, requiring continued support with luteinizing hormone-releasing hormone (LHRH) agonists, with or without androgens, may continue treatment.
•6.Use of strong or moderate inducers of CYP3A (Flockhart, 2007), including certain herbal medications (eg, St.John’s Wort) within 14 days or 5× the half-life (whichever is longer) prior to the first dose of study drug through the end of treatment
•7.Participant has known active central nervous system metastases
•8.Participants with a history or current evidence of central serous retinopathy (CSR) or retinal vein occlusion (RVO) or predisposing factors to CSR or RVO (ie, uncontrolled glaucoma or ocular hypertension, uncontrolled diabetes mellitus, hyperviscosity or hypercoagulability syndromes) or other evidence of retinal pathology considered a risk factor for RVO or CSR. Glaucoma diagnosed within 1 month prior to Cycle1 Day1.
•9.History of retinal degenerative disease
•10.Hepatobiliary diseases including biliary tract diseases, autoimmune hepatitis, inflammation, fibrosis, cirrhosis of liver caused by viral, alcohol, or genetic reasons
•11.Participants who have New York Heart Association Class II-IV heart disease, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, poorly controlled hypertension (defined as systolic >150 mmHg or diastolic blood pressure >90 mmHg), or congestive heart failure
•12.Left ventricular ejection fraction (LVEF) <50% at screening
•13.Arterial thrombotic or embolic events such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 6 months before the first dose of study drug
•Expansion Phase:
•1.Previous treatment with any other systemic GIST therapy other than imatinib.
•2.Received imatinib treatment less than 10 days prior to the first dose of study drug.
•3.Prior therapy with a MEK inhibitor.
•4.Participants with a prior or concurrent malignancy whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of this clinical trial. For example, participants receiving adjuvant cancer treatment are not eligible if those medications are potentially active against the disease under study or excluded per protocol. NOTE: Participants with a history of breast cancer, requiring continued hormonal treatment (e.g. anti-estrogen or an aromatase inhibitor) may continue treatment. Participants with a history of prostate cancer, requiring continued support with luteinizing hormone-releasing hormone (LHRH) agonists, with or without androgens, may continue treatment.
•5.Use of stro

研究者

发起方

Deciphera Pharmaceuticals, LLC

相似试验

进行中（未招募）

1 期

A Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide in Patients with Worsening (relapsed) or Unresponsive (refractory) Diffuse Large B-Cell Lymphoma (R/R DLBCL) (MINDway)Diffuse Large B-Cell Lymphoma (DLBCL)MedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2021-003855-40-CZMorphoSys AG51

进行中（未招募）

1 期

EUCTR2021-003855-40-ATMorphoSys AG51

进行中（未招募）

1 期

EUCTR2021-003855-40-ESMorphoSys AG51

进行中（未招募）

1 期

EUCTR2021-003855-40-PLMorphoSys AG51

进行中（未招募）

1 期

A Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide in Patients with Worsening (relapsed) or Unresponsive (refractory) Diffuse Large B-Cell Lymphoma (R/R DLBCL) (MINDway)Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)MedDRA version: 21.0Level: PTClassification code: 10012818Term: Diffuse large B-cell lymphoma Class: 100000004864

CTIS2023-507993-42-00MorphoSys AG51